cat no | io1087, io1088, io1089
ioGlutamatergic Neurons SNCA A53T/A53T™
Human iPSC-derived Parkinson's disease model
A rapidly maturing, consistent and scalable isogenic system to study Parkinson’s disease (PD).
ioGlutamatergic Neurons SNCA A53T/A53T are opti-ox™ precision reprogrammed glutamatergic neurons carrying a genetically engineered homozygous A53T mutation in the SNCA gene encoding the alpha-synuclein protein.
Place your order
Confidently investigate your phenotype of interest across multiple clones with our disease model clone panel. Detailed characterisation data (below) and bulk RNA sequencing data (upon request) help you select specific clones if required.
Benchtop benefits
Make True Comparisons
Pair the ioDisease Model Cells with the genetically matched wild-type ioGlutamatergic Neurons to directly investigate the effect of the alpha-synuclein mutation on cellular and molecular mechanisms and cell function.
Scalable
With opti-ox technology, we can make billions of consistently reprogrammed cells, surpassing the demands of industrial workflows.
Quick
The disease model cells and isogenic control are experiment ready as early as 2 days post revival, and form structural neuronal networks at 11 days.
Highly characterised and defined
ioGlutamatergic Neurons SNCA A53T/A53T express neuron-specific markers comparably to the wild type control
Immunofluorescent staining on post-revival day 11 demonstrates similar homogenous expression of pan-neuronal proteins MAP2 and TUBB3 (left tab) and glutamatergic neuron-specific transporter VGLUT2 (right tab) in ioGlutamatergic Neurons SNCA A53T/A53T clones compared to the genetically matched control. 100X magnification.
ioGlutamatergic Neurons SNCA A53T/A53T form structural neuronal networks by day 11
ioGlutamatergic Neurons SNCA A53T/A53T clones mature rapidly and form structural neuronal networks over 11 days, highly similar to the genetically matched control. Day 1 to 11 post thaw; 100X magnification.
ioGlutamatergic Neurons SNCA A53T/A53T demonstrate gene expression of neuronal-specific and glutamatergic-specific markers following reprogramming
Gene expression analysis demonstrates that ioGlutamatergic Neurons SNCA A53T/A53T clones and wild-type ioGlutamatergic Neurons (WT Control) lack the expression of pluripotency markers (NANOG and OCT4) at day 11, whilst robustly expressing pan-neuronal (TUBB3 and SYP) and glutamatergic-specific (VGLUT1 and VGLUT2) markers, as well as the glutamate receptor GRIA4. Gene expression levels were assessed by RT-qPCR (data normalised to HMBS; cDNA samples of the parental human iPSC line (hiPSC) were included as reference). Data represents day 11 post-revival samples, n=2 replicates.
Disease-related SNCA is expressed in ioGlutamatergic Neurons SNCA A53T/A53T following reprogramming
RT-qPCR analysis demonstrates a similar expression level of the SNCA gene in both wild type ioGlutamatergic Neurons (WT Control) and ioGlutamatergic Neurons SNCA A53T/A53T clones at day 11 post-revival (n=2 replicates). cDNA samples of the parental human iPSC line (hiPSC) were included as a reference.
Cells arrive ready to plate
ioGlutamatergic Neurons SNCA A53T/A53T are delivered in a cryopreserved format and are programmed to mature rapidly upon revival in the recommended media. The protocol for the generation of these cells is a two-phase process: Phase 1, Stabilisation for 4 days; Phase 2, Maintenance, during which the neurons mature. Phases 1 and 2 after revival of cells are carried out by the customer.
Industry leading seeding density
The recommended minimum seeding density is 30,000 cells/cm2, compared to up to 250,000 cells/cm2 for other similar products on the market. One small vial can plate a minimum of 0.7 x 24-well plate, 1 x 96-well plate, or 1.5 x 384-well plates. This means every vial goes further, enabling more experimental conditions and more repeats, resulting in more confidence in the data.
Generation and characterisation of a panel of human iPSC-derived neurons and microglia carrying early and late onset relevant mutations for Alzheimer’s disease
Downlaod
ioGlutamatergic Neurons Wild Type and related disease models | User Manual
Download
Generating publishable neuroscience research in 12 weeks with ioGlutamatergic Neurons™
Download
Running Large-Scale CRISPR Screens in Human Neurons
Watch now
3D bioprinting of iPSC neuron-astrocyte coculture
Read more
Hoescht(blue)TUBB3(blue)_day4.jpg?width=604&name=bit.bio_ioGlutamatergic%20Neurons_60xMAP2(red)Hoescht(blue)TUBB3(blue)_day4.jpg)
Addressing the Reproducibility Crisis | Driving Genome-Wide Consistency in Cellular Reprogramming
Watch now
Industrialising Cellular Reprogramming: Leveraging opti-ox™ Technology to Manufacture Human Cells with Unprecedented Consistency
Watch now
Modelling neurodegeneration: Human isogenic system to study FTD & ALS
Download
Hoescht(blue)_day12v2.png?width=604&name=bit.bio_ioGlutamatergic%20Neurons_20xMAP2(red)Hoescht(blue)_day12v2.png)
Rethinking Developmental Biology With Cellular Reprogramming
Watch now
.png?width=604&name=Tech%20Nets%20online%20symposium%20header%20(1).png)
Precision Cellular Reprogramming for Scalable and Consistent Human Neurodegenerative Disease Models
Watch now
Development and characterisation of a robust in vitro disease model to study tauopathies
Download
Validation of ALS-relevant phenotypes in precision reprogrammed iPSC-derived glutamatergic Neurons containing a TDP-43 M337V mutation.
Download
Rapid and consistent generation of functional microglia from reprogrammed hiPSCs to study neurodegeneration and neuroinflammation
Download
_MAP2(R)_DAPI(B)_%20(1).png?width=604&name=a-HTT50CAGWT_Overlay__TUBB3(G)_MAP2(R)_DAPI(B)_%20(1).png)
Developing next-generation in vitro phenotypic assays for Huntington’s disease by combining a precision reprogrammed hiPSC-derived disease model with high-density microelectrode arrays
Download
Interferon-γ exposure of human iPSC-derived neurons alters major histocompatibility complex I and synapsin protein expression | Publication
Read more
Glutamatergic Neurons and Brain Cyst Formation | Publication
Read more
Cell culture hacks | human iPSC-derived glutamatergic neurons
Read this blog on glutamatergic neuron cell culture for our top tips on careful handling, cell plating and media changes to achieve success from the outset.
.png?width=1860&height=1260&name=bit.bio_3x2_ioGlutamatergic%20Neurons_MAP2_Hoescht_x20_hi.res%20(1).png)
ioDisease Model Cells
ioGlutamatergic Neurons PRKN R275W/WT™
cat no. io1013
Order now
ioDisease Model Cells
ioGlutamatergic Neurons GBA null/R159W™
cat no. io1007
Order now
ioWild Type Cells
ioGlutamatergic Neurons™
cat no. io1001
Order now
ioCRISPR-Ready Cells
CRISPR-Ready ioGlutamatergic Neurons™
cat no. ioEA1090
Order now
ioDisease Model Cells
ioGlutamatergic Neurons PRKN R275W/R275W™
cat no. io1020
Order now
Wild Type and Isogenic Disease Model cells: A true comparison
Further your disease research by pairing our wild type cells with isogenic disease models.
